
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health, Inc. demonstrated strong financial performance in 2024, achieving a 31% year-over-year revenue growth and exceeding expectations with fourth-quarter revenues of $202 million, reflecting a 30% increase from the previous year. The company's adjusted gross margin improved to 63%, supported by favorable reimbursement trends and an increase in the Guardant360 LDT Medicare rate, which is projected to boost revenues further. Additionally, with clinical volumes rising by 24% year-over-year and ongoing advancements in product offerings, including the FDA approval of the Shield test for colorectal cancer screening, Guardant is well-positioned for continued growth in the oncology market.
Bears say
Guardant Health faces several fundamental challenges that contribute to a negative outlook on its stock. The slower-than-anticipated growth of its therapy selection franchise, coupled with weaker-than-estimated adoption rates for its MRD testing and the potential for the Shield test to be excluded from the USPSTF guidelines, poses significant risks to its revenue projections. Furthermore, downward pressure on the average selling price (ASP) of Shield, competitive market dynamics, and difficulties in securing reimbursement for its tests underscore the financial uncertainties affecting the company's future performance.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares